UY35447A - Moduladores de p2x7 - Google Patents

Moduladores de p2x7

Info

Publication number
UY35447A
UY35447A UY0001035447A UY35447A UY35447A UY 35447 A UY35447 A UY 35447A UY 0001035447 A UY0001035447 A UY 0001035447A UY 35447 A UY35447 A UY 35447A UY 35447 A UY35447 A UY 35447A
Authority
UY
Uruguay
Prior art keywords
formula
modulators
compounds
substituents
preparing
Prior art date
Application number
UY0001035447A
Other languages
English (en)
Inventor
Michael A Letavic
Dale A Rudolph
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY35447A publication Critical patent/UY35447A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se dirige a un compuesto de la Fórmula (I): en donde los sustituyentes son tales como se establecen en las reivindiaciones. La invención se relaciona, además, con composiciones farmacéuticas que comprenden los compuestos de la Fórmula (I). Los métodos para preparar y usar los compuestos de la Fórmula (I) están, además, dentro del alcance de la invención.
UY0001035447A 2013-03-14 2014-03-14 Moduladores de p2x7 UY35447A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361785558P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
UY35447A true UY35447A (es) 2014-09-30

Family

ID=50631041

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035447A UY35447A (es) 2013-03-14 2014-03-14 Moduladores de p2x7

Country Status (10)

Country Link
US (3) US9540388B2 (es)
EP (2) EP3309161B1 (es)
JP (1) JP6294954B2 (es)
AR (1) AR095421A1 (es)
ES (2) ES2776654T3 (es)
HK (2) HK1218649A1 (es)
JO (1) JO3509B1 (es)
TW (1) TWI627174B (es)
UY (1) UY35447A (es)
WO (1) WO2014152621A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053463B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
WO2014152589A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
EA034015B1 (ru) * 2014-09-12 2019-12-19 Янссен Фармацевтика Нв Модуляторы р2х7
PL3287443T3 (pl) 2015-04-24 2022-02-21 Shionogi & Co., Ltd 6-członowa pochodna heterocykliczna i kompozycja farmaceutyczna ją zawierająca
MA45011A (fr) * 2015-09-04 2021-06-02 Janssen Pharmaceutica Nv Composé thérapeutique contre la douleur et sa synthèse
CN105596301A (zh) * 2016-01-29 2016-05-25 中国药科大学 一种以异喹啉为基本骨架的p2x7受体拮抗剂的纳米混悬剂及其制备方法
CN105503884B (zh) * 2016-02-17 2017-10-13 上海皓元生物医药科技有限公司 一种用于合成bet蛋白抑制剂的关键中间体的合成方法
BR112019006675A2 (pt) * 2016-10-17 2019-06-25 Shionogi & Co derivado heterocíclico nitrogenado bicíclico e composição farmacêutica contendo o mesmo
EP3856178A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
US20200102311A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol Lipase Modulators
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
MX2022003819A (es) 2019-09-30 2022-05-11 Janssen Pharmaceutica Nv Ligandos de pet de mgl radiomarcados.
KR20220157999A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US905687A (en) 1908-07-14 1908-12-01 Samuel W Evans Jr Folding umbrella and cane.
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
AU2003244632A1 (en) 2002-07-25 2004-02-25 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
US7625888B2 (en) 2004-08-23 2009-12-01 Merck & Co., Inc. Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
JP2008528580A (ja) 2005-01-27 2008-07-31 アストラゼネカ・アクチエボラーグ Ｐ２ｘ７受容体の阻害剤である新規二環式芳香族化合物
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
WO2009002423A2 (en) 2007-06-21 2008-12-31 Schering Corporation Polycyclic guanine derivatives and use thereof
EA020332B1 (ru) 2007-08-10 2014-10-30 Х. Лундбекк А/С Аналоги гетероариламидов
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
WO2009132000A1 (en) 2008-04-22 2009-10-29 Janssen Pharmaceutica Nv Quinoline or isoquinoline substituted p2x7 antagonists
US8309578B2 (en) 2008-11-25 2012-11-13 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
EP2424869B1 (en) * 2009-04-29 2016-06-22 Glaxo Group Limited 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US8871760B2 (en) 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
SI2552920T1 (sl) 2010-04-02 2017-07-31 Ogeda Sa Nove nk-3 receptor selektivne antagonist spojine, farmacevtski sestavki in postopki za uporabo pri nk-3 receptor posredovanih motnjah
CN102844507A (zh) 2010-04-16 2012-12-26 罗德里戈·格拉夫费尔南德斯 用于建筑物的可折叠结构
WO2012040048A2 (en) 2010-09-21 2012-03-29 Schering Corporation Triazolopyrazinones as p2x7 receptor antagonists
EA026393B1 (ru) 2012-05-22 2017-04-28 Дженентек, Инк. N-замещенные бензамиды и их применение в лечении боли
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
EP2906538A4 (en) 2012-10-15 2016-05-11 Epizyme Inc SUBSTITUTED BENZOL COMPOUNDS
EP2909192B1 (en) 2012-10-16 2017-05-17 Janssen Pharmaceutica NV Methylene linked quinolinyl modulators of ror-gamma-t
NZ707495A (en) 2012-11-01 2019-01-25 Incyte Holdings Corp Tricyclic fused thiophene derivatives as jak inhibitors
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
CA2895808A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
PL2935248T3 (pl) 2012-12-21 2018-07-31 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania dla nich
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
KR20150119012A (ko) 2013-02-08 2015-10-23 셀진 아빌로믹스 리서치, 인코포레이티드 Erk 억제제 및 이의 용도
NO335177B1 (no) 2013-03-06 2014-10-13 Cambi Technology As Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse
SI2964229T1 (sl) 2013-03-06 2020-02-28 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidin modulatorji receptorja histamina H4
WO2014152589A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
US10053463B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
UA118549C2 (uk) 2013-03-14 2019-02-11 Ґлаксосмітклайн Інтеллекчуал Проперті (№ 2) Лімітед 2,3-дизаміщені похідні 1-ацил-4-аміно-1,2,3,4-тетрагідрохіноліну та їх застосування як інгібіторів бромодомену
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
EP2976332B1 (en) 2013-03-14 2018-01-31 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization.
MX2015012028A (es) 2013-03-14 2016-02-11 Curadev Pharma Private Ltd Inhibidores de la ruta de quinurenina.
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
SG11201507382QA (en) 2013-03-14 2015-10-29 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
WO2014154897A1 (en) 2013-03-29 2014-10-02 Euroscreen Sa NOVEL N-ACYL-(3-SUBSTITUTED)-(8-METHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
EA034015B1 (ru) 2014-09-12 2019-12-19 Янссен Фармацевтика Нв Модуляторы р2х7
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines

Also Published As

Publication number Publication date
HK1218649A1 (zh) 2017-03-03
ES2652648T3 (es) 2018-02-05
US10053462B2 (en) 2018-08-21
WO2014152621A1 (en) 2014-09-25
EP2970287B1 (en) 2017-11-01
US9540388B2 (en) 2017-01-10
TW201522339A (zh) 2015-06-16
US20140275056A1 (en) 2014-09-18
EP3309161A1 (en) 2018-04-18
AR095421A1 (es) 2015-10-14
EP3309161B1 (en) 2019-12-18
ES2776654T3 (es) 2020-07-31
US20170088550A1 (en) 2017-03-30
JP2016513702A (ja) 2016-05-16
JO3509B1 (ar) 2020-07-05
US20160039836A1 (en) 2016-02-11
HK1254111A1 (zh) 2019-07-12
EP2970287A1 (en) 2016-01-20
JP6294954B2 (ja) 2018-03-14
US9102686B2 (en) 2015-08-11
TWI627174B (zh) 2018-06-21

Similar Documents

Publication Publication Date Title
UY35447A (es) Moduladores de p2x7
UY35469A (es) Moduladores de p2x7
UY35409A (es) 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
UY35408A (es) 7-azabiciclos sustituidos y su uso como moduladores del receptor de orexina
CU20140143A7 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2016000145A (es) Reguladores de nrf2
SV2014004770A (es) Nuevos derivados de pirrol, su procedimiento de preparación y los composiciones farmacéuticas que los contienen
UY35410A (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
CR20150370A (es) Compuestos antivirales
ECSP13013074A (es) Nuevos derivados de piridina
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35467A (es) Compuestos orgánicos
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
CR20150447A (es) Nuevos derivados de pirazol
CR20150250A (es) Nuevos derivados de piridina
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
CR20150204A (es) Nuevos derivados de piridina
CR20150440A (es) Nuevos derivados de piridina
CR20160072A (es) Compuestos y composiciones como inhibidores de la mek
CR20150511A (es) Nuevos derivados de purina
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
CR20160459A (es) Nuevos derivados de piridina
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35653A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen